Physician profile
Patrick Vanschoyck
NPI 1124088083
$2,699.15
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $516 · 2021: $663 · 2022: $406 · 2023: $130 · 2024: $44.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $174.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $631.04 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $265.85 | 2019-2024 | Flumist Quadrivalent, Airsupra |
| Glaxosmithkline, LLC. | $221.99 | 2019-2021 | |
| Amarin Pharma, INC. | $176.09 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $124.90 | 2021 | |
| Novartis Pharmaceuticals Corporation | $119.13 | 2019-2020 | |
| Abbvie INC. | $108.38 | 2020-2022 | |
| Daiichi Sankyo INC. | $91.65 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.19 | 2019-2020 | |
| Abbott Laboratories | $85.35 | 2019-2022 | |
| Amgen INC. | $84.84 | 2019-2023 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $72.56 | 2019-2021 | |
| Horizon Therapeutics Plc | $72.09 | 2021-2022 | |
| Gilead Sciences, INC. | $70.12 | 2021-2023 | |
| Mylan Specialty L.P. | $62.96 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $61.81 | 2019-2021 | |
| Biogen, INC. | $56.76 | 2021 | |
| Astellas Pharma US INC | $53.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.13 | 2019-2021 | |
| Medtronic, INC. | $28.45 | 2022-2024 | Intellis Adaptivestim |
| Jazz Pharmaceuticals INC. | $26.48 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.24 | 2019-2021 | |
| Allergan, INC. | $25.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.71 | 2021 | |
| Fisher & Paykel Healthcare INC | $20.12 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.93 | 2020 | |
| Alk-Abello, INC | $14.65 | 2019 | |
| Medtronic USA, INC. | $12.92 | 2020 | |
| Genentech USA, INC. | $12.03 | 2019 | |
| Eisai INC. | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Vanschoyck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.